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Abstract. A potential role may be played by receptor-type 
protein tyrosine phosphatase kappa (PTPRK) in angiogen-
esis due to its critical function in coordinating intracellular 
signal transduction from various receptors reliant on tyrosine 
phosphorylation. In the present study, we investigated the 
involvement of PTPRK in the cellular functions of vascular 
endothelial cells (HECV) and its role in angiogenesis 
using in vitro assays and a PTPRK knockdown vascular 
endothelial cell model. PTPRK knockdown in HECV cells 
(HECVPTPRKkd) resulted in a decrease of cell proliferation 
and cell-matrix adhesion; however, increased cell spreading 
and motility were seen. Reduced focal adhesion kinase 
(FAK) and paxillin protein levels were seen in the PTPRK 
knockdown cells which may contribute to the inhibitory 
effect on adhesion. HECVPTPRKkd cells were more responsive 
to the treatment of fibroblast growth factor (FGF) in their 
migration compared with the untreated control and cells 
treated with VEGF. Moreover, elevated c-Src and Akt1 were 
seen in the PTPRK knockdown cells. The FGF-promoted 
cell migration was remarkably suppressed by an addition 
of PLCγ inhibitor compared with other small inhibitors. 
Knockdown of PTPRK suppressed the ability of HECV 
cells to form tubules and also impaired the tubule formation 
that was induced by FGF and conditioned medium of cancer 
cells. Taken together, it suggests that PTPRK plays dual roles 
in coordinating angiogenesis. It plays a positive role in cell 
proliferation, adhesion and tubule formation, but suppresses 
cell migration, in particular, the FGF-promoted migration. 
PTPRK bears potential to be targeted for the prevention of 
tumour associated angiogenesis.
Introduction
Vasculogenesis/angiogenesis is an essential process for 
embryonic and postnatal development, wound healing and 
also endometrial angiogenesis during the menstrual cycle in 
women. Angiogenesis is also vital for the growth and dissemi-
nation of solid tumours (1,2). Tumour-associated angiogenesis 
is pivotal for a solid tumour to grow beyond a certain size 
(2-3 mm) as it can be restricted by interspatial diffusion of 
nutrients. The newly formed vasculature also provides a 
pathway for cancer cells to spread to other parts of the body. 
Angiogenesis is affected by multiple factors and various cells 
in the tumour microenvironment (3).
Angiogenesis can be induced or promoted by pro-angio-
genic factors, such as VEGF, FGF, TNF-α and HGF which 
can be produced by cancer cells, stromal cells, inflammatory 
cells and endothelial cells (4-7). For example, VEGF binds 
to two tyrosine kinase receptors, VEGFR1 and VEGFR2. 
VEGFR1 is expressed by hematopoietic and vascular endo-
thelial cells and acts as a negative regulator of angiogenesis, 
whilst VEGFR2 is mainly expressed by vascular endothelial 
cells and is crucial for vasculogenesis leading to the forma-
tion of primary vascular plexus (8-10). Tie-2 receptor and its 
ligands, angiopoietins, are also important for angiogenesis. 
Angiopoietin-2 has been demonstrated as a VEGF negative 
regulator in several cancers (11,12). In addition to their pro-
angiogenic effect, FGF and HGF can also directly promote 
proliferation, migration and invasion of cancer cells (13,14).
Protein tyrosine phosphatases (PTPs) are involved in regu-
lation of cellular functions by coordinating signal transduction 
through dephosphorylation of certain signalling molecules. 
PTPs have also been indicated as important regulators in 
tumorigenesis and angiogenesis (15-18). Receptor-like protein 
tyrosine phosphatase beta (PTPRB, also known as vascular 
endothelial VE-PTP), for example, plays a crucial role in the 
angiogenesis of breast cancer by regulating several signalling 
pathways such as the Tie-2 pathway (19). Blocking PTPRB 
with a small inhibitor, AKB-9778, reduced tumour growth and 
metastases of breast cancer (20). Furthermore, Src homology 2 
domain-containing protein tyrosine phosphatase-1 (SHP-1) 
suppresses angiogenesis by inhibiting the VEGF signalling in 
microvascular endothelial cells (21).
To date, aberrant expression of receptor-like protein 
tyrosine phosphatase kappa (PTPRK) has been observed 
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in glioma, lymphoma, prostate and breast cancer (22-26). 
However, the role played by PTPRK in angiogenesis remains 
largely unknown. The present study aimed to investigate the 
role played by this molecule in angiogenesis, in particular 
VEGF and FGF-promoted angiogenesis.
Materials and methods
Cell lines and cells culture. HECV (human endothelial 
vascular cell line) cells were purchased from Interlab 
(Naples, Italy); PANC-1, MSA-MB-231 and MRC-5 cells 
were purchased from the American Type Culture Collection 
(ATCC; Manassas, VA, USA) and HT115 cells were purchased 
from the European Collection of Authenticated Cell Cultures 
(ECACC; Salisbury, UK). Cells were routinely cultured with 
Dulbecco's modified Eagle's medium (DMEM) containing 
10% fetal calf serum (FCS) and antibiotics at 37˚C with 5% 
CO2. PCR primers were designed using Primer-3 and synthe-
sised by Sigma-Aldrich (Dorset, UK) and the sequences are 
provided in Table I.
Reverse transcription-PCR. Total RNA extraction from cells 
was performed using Tri reagent (Sigma-Aldrich). Following 
reverse transcription, PCR was carried out using GoTaq 
DNA olymerase (Promega, Southampton, UK). Reactions 
were carried out with the following process: 94˚C for 5 min, 
30 cycles of 94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 
30 sec, followed by a final extension of 7 min at 72˚C. PCR 
products were separated on a 1.5% agarose gel and photo-
graphed after staining with SYBR Safe DNA dye (Invitrogen, 
Paisley, UK).
Real-time quantitative PCR. The level of PTPRK transcripts 
in HECV cells was determined using a real-time quantitative 
PCR, based on a previously reported method (27). The reac-
tion was carried out on an iCycler iQ™ (Bio-Rad Laboratories, 
Hempstead, UK) which is equipped with an optical unit that 
allows real-time detection of 96 reactions. The reaction condi-
tions were: 94˚C for 12 min, 100 cycles of 94˚C for 15 sec, 
55˚C for 35 sec (the data capture step) and 72˚C for 15 sec. 
The levels of the transcripts were generated from an internal 
standard that was simultaneously amplified.
Construction of ribozyme transgene targeting human PTPRK 
and the establishment of corresponding stable transfectants. 
Anti-human PTPRK hammerhead ribozymes were designed 
based on the secondary structure of the gene transcript and 
generated using the Zuker RNA Mfold program (28). The 
ribozymes were synthesized and then cloned into a 
pEF6/V5-His TOPO vector (Invitrogen). The verified ribo-
zyme transgenes and empty plasmids were transfected into 
HECV (HECVPTPRKkd and HECVpEF) cells, respectively using 
an Easyjet Plus electroporator (Equibio, Kent, UK). After a 
period of selection with 5 µg/ml blasticidin (up to 10 days), the 
verified transfectants were cultured in maintenance medium 
containing 0.5 µg/ml blasticidin. Primer sequences of the 
ribozymes were 5'-CTGCAGTTTGCTCTTTTTTACAATT 
AATATCTGATGAGTCCGTGAGGA-3' and 5'-ACTAGTTC 
ATCCTCCTTCTCCTAGTTGTTTCGTCCTCACGGACT-3'.
In vitro cell growth assay. HECV cells (3,000 cells/well) 
were plated into two identical 96-well plates. Cells were 
fixed in 4% formalin after 24 and 72 h of culture. The cells 
were then stained with 0.5% (w/v) crystal violet. Following 
washing, stained crystal violet was extracted with 10% 
(v/v) acetic acid (29). Absorbance was then determined at a 
wavelength of 540 nm using an ELx800 spectrophotometer 
(BioTek Instruments, Inc., Swindon, UK). Growth rate of day 
3 (%) = absorbance of day 3/absorbance of day 1 x 100.
In vitro cell-matrix adhesion. Cells (20,000/well) were seeded 
to each well of a 96-well plate which was pre-coated with 
Matrigel (5 µg/well) (BD Biosciences, Oxford, UK). After 
40 min of incubation, the non-adherent cells were washed 
off using balanced salt solution (BSS; comprising 137 mM 
NaCl, 2.6 mM KCl, 1.7 mM Na2HPO4 and 8.0 mM KH2PO4 
and adjusting the pH to 7.4 with 1 M NaOH). The remaining 
cells were fixed with formalin and were stained with crystal 
violet. The number of adherent cells was then counted under 
a microscope.
In vitro migration/wounding assay. Cells (200,000/well) were 
seeded into a 24-well plate and allowed to reach confluence. 
The cell monolayer was scratched using a fine gauge needle 
to create an artificial wound of ~200 µm in width (30). Images 
were taken at 0.25, 1, 2, 3 and 4 h after wounding. Migration 
distances were measured using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA).
Cell spreading assay. Cells (20,000/well) were seeded into a 
96-well plate which was pre-coated with Matrigel (5 µg/well) 
(BD Biosciences) and the cells were fixed after an incubation 
of up to 4 h. The fixed cells were stained with fluorescein 
phalloidin (F432; Life Technologies, Carlsbad, CA, USA) 
and DAPI (10236276001; Roche Applied Science, Basel, 
Switzerland). Images were taken using a Leica fluorescence 
Table I. Primer sequences used in the present study.
Gene Forward primers (5'-3') Reverse primer (5'-3')
GAPDH GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
GAPDH (Q-PCR) CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGACCCTTTTG
PTPRK AATTACAATTGATGGGGAGA CCACTTTTCCACCTGAAGTA
PTPRK (Q-PCR) AATTACAATTGATGGGGAGA ACTGAACCTGACCGTACATATTGTGTGACGATGAAAGC
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microscope (Leica DM IL LED). Cell spreading was measured 
using ImageJ software (National Institutes of Health).
Tubule formation assay. Cells (40,000/well) were seeded 
into a 96-well plate which was pre-coated with Matrigel 
(500 µg/well). The cells were fixed with formalin after a 4-h 
incubation and photographed immediately using a microscope. 
The sum of tubule perimeter was measured using ImageJ 
software.
Electric cell-substrate impedance sensing (ECIS). An 
ECIS 9600 model instrument and 96W1E arrays (Applied 
Biophysics, Inc., Troy, NY, USA) was also used for migration 
assays in the study, as previously reported (31). HECVpEF and 
HECVPTPRKkd cells were seeded at 40,000 cells/well in 200 µl 
DMEM medium alone or supplemented with 10 ng/ml FGF 
(F0291; Sigma-Aldrich) or 10 ng/ml VEGF (293-VE; R&D 
Systems, Abingdon, UK), with small inhibitors; 5 µM Akt 
inhibitor (Akt124005; Millipore UK, Ltd., Watford, UK), 
50 nM c-Src inhibitor Src I1 (Tocris Bioscience, Bristol, UK), 
5 nM PI3K inhibitor (wortmannin; Tocris Bioscience) and 
5 nM PLCg inhibitor (STK870702; Vitas-M Laboratory, Ltd., 
Apeldoorn, The Netherlands), respectively. The resistance was 
measured at 30 kHZ for 5 h after electrical wounding, and data 
was analysed using an ECIS-9600 software package.
Western blot analysis. Equal amounts of protein were separated 
using SDS-PAGE and blotted onto nitrocellulose membranes 
(SC-3724; Santa Cruz Biotechnology, Heidelberg, Germany). 
Proteins were then probed with the primary antibodies and 
corresponding peroxidase-conjugated secondary antibodies. 
Protein bands were visualised using a chemiluminescence 
detection kit (Luminata; Millipore) and photographed using 
UVItec imager (Uvitec Printing Ink Co., Inc., Lodi, NJ, USA). 
Antibodies for GAPDH (sc-32233), PTPRK (sc-28906), c-Src 
(sc-5266), PLCγ (sc-81) and Akt1 (sc-1618) were purchased 
from Santa Cruz Biotechnology. Antibodies for FAK and 
Paxillin were obtained from BD Biosciences.
Statistical analysis. Statistical analysis was performed using 
SigmaPlot 11 (SPSS, Inc., Chicago, IL, USA). Data were 
calculated as the mean ± SD, the Student's t-test was used for 
normally distributed data and one-way ANOVA was used for 
multiple group comparison. Each assay was performed three 
times. P<0.05 was considered statistically significant.
Results
Knockdown of PTPRK in vascular endothelial cells using 
anti-PTPRK ribozyme. The expression of PTPRK in the 
vascular endothelial cell line HECV, was first determined 
using conventional PCR with a comparison to its expression in 
several cancer cell lines including colorectal cancer (HT115), 
pancreatic cancer (PANC-1) and breast cancer (MDA-MB-231) 
and also a fibroblast cell line (MRC-5) (Fig. 1A). All these cell 
lines express PTPRK though levels had subtle variations.
The expression of PTPRK was knocked down using ribo-
zyme transgenes targeting human PTPRK mRNA. Reduced 
mRNA expression of PTPRK was seen in the cells which 
were transfected with anti-PTPRK ribozyme transgenes using 
both conventional PCR (Fig. 1B) and real-time quantita-
tive PCR (Fig. 1D). The knockdown of PTPRK was further 
confirmed with western blot analysis for its protein expression 
(Fig. 1C and E).
Effect of PTPRK knockdown on the proliferation and cell-
matrix adhesion of endothelial vascular cells. After verification 
of the knockdown of PTPRK, we also examined its influence 
Figure 1. PTPRK gene expression and knockdown of PTPRK in HECV cells. (A) Expression of PTPRK mRNA in different cell lines (HT115, colon cancer 
cell; PANC-1, pancreatic cancer cell; MDA-MB-231, breast cancer cell; MRC-5, lung fibroblast cell; HECV, endothelial cell). Knockdown of PTPRK was seen 
in HECVPTPRKkd cells compared with empty plasmid control (HECVpEF cells) using RT-PCR (B), western blot analysis (C) and real-time quantitative PCR (D). 
(E) PTPRK protein band volume of three repeats which is normalised against corresponding internal control. The intensity shown is integrated band intensity 
(intensity x area) and was normalised against the corresponding GAPDH signal. *P<0.05.
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on cell proliferation and cell-matrix adhesion. Knockdown 
of PTPRK significantly reduced proliferation of the vascular 
endothelial cells compared to the control cells (276.27±16.37 
vs. 314.77±21.93%; P<0.01) (Fig. 2A). PTPRK knockdown 
elicited a significant influence on cell matrix adhesion. The 
number of adhered HECVPTPRKkd cells (33.33±7.27) was much 
less than the HECVpEF cells (163.50±12.96), P<0.001 (Fig. 2B). 
Furthermore, knockdown of PTPRK resulted in a reduced 
expression of both FAK and paxillin proteins (Fig. 2C).
PTPRK and the migration and spreading of endothelial 
vascular cells. PTPRK knockdown cells exhibited increased 
cell motility compared with the control cells. After a 4-h 
incubation, the distance that HECVPTPRKkd cells migrated 
was 152.02±18.98 µm compare with that of HECVpEF cells 
(102.91±11.26 µm), P<0.001 (Fig. 3A). Cell spreading assays 
showed a very interesting result. After a 30-min incuba-
tion, the size of HECVpEF cells were found to be larger than 
HECVPTPRKkd (120.98±4.66 vs. 102.82±4.25 µm; P<0.05) 
Figure 2. The effects of PTPRK knockdown on cell adhesion of HECV cells. (A) Knockdown of PTPRK reduced cell-matrix adhesion in HECV cells. **P<0.01. 
(B) Reduced expression of PTPRK resulted a decrease in cell-matrix adhesion in HECV cells. ***P<0.001. (C) FAK and paxillin protein expression levels were 
decreased in the PTPRK knockdown HECV cells.
Figure 3. The effects of PTPRK knockdown on cell migration and spreading of HECV cells. (A) Knockdown of PTPRK in HECV cells increased cell motility. 
(B) Bar graph showed average size of HECV cells at different time points (0.5, 1, 2 and 4 h). (C) Immunofluorescent of phalloidin in HECV cells at different 
time points. *P<0.05 and ***P<0.001.
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which appeared to be in line with the inhibitory effect on 
cell-matrix adhesion. Such an effect was diminished after 
1-h incubation. However, an increased spreading was seen in 
the HECVPTPRKkd cells after 2-h incubation, their size being 
244.20±12.93 ImageJ units, ~30% bigger than the size of 
HECVpEF cells (186.76±8.29 ImageJ units; P<0.001). A similar 
influence on the spreading was also observed after an incuba-
tion of 4 h (Fig. 3B and C).
PTPRK in VEGF and FGF induced migration of vascular 
endothelial cells. VEGF and FGF pathways play crucial roles 
for several cell functions including vasculogenesis and angio-
genesis (8,32). To explore the involvement of PTPRK in VEGF 
and FGF induced angiogenesis, we determined the migration 
of HECV cells with additions of VEGF and FGF, respectively. 
Little effect on cell migration was seen in the HECVpEF cells 
exposed to VEGF (10 ng/ml) and FGF (10 ng/ml), respectively. 
However, the knockdown of PTPRK conferred an increased 
sensitivity to these two pro-angiogenic factors. HECVPTPRKkd 
cells were more responsive to the treatment of both VEGF 
and FGF. A more marked increase was seen in FGF treated 
HECVPTPRKkd cells (Fig. 4A and B). We then examined the 
Figure 4. The FGF signalling pathway participates in regulating cell motility of PTPRK knockdown cells. (A) Incubation of HECVPTPRKkd cells with rhFGF 
promoted cell motility significantly. (B) The overall changes of resistance on the fifth hour with statistical analysis. (C) Alteration of c-Src, PLCγ and Akt1 
proteins in PTPRK knockdown HECV cells and their responses to a 2-h treatment of FGF and VEGF, respectively. (D) Involvement of PI3K, Src, Akt1 
and PLCγ in the FGF-promoted migration of the HECV cells with PTPRK knockdown. We used the ECIS to determine cell migration of HECV cells with 
additions of small inhibitors targeting these molecules. The curves are average resistance of each group over a period up to 5 h. (E) The overall changes of 
resistance on the fifth hour with statistical analysis. Both HECVpEF and HECVPTPRKkd cells were treated with FGF alone or in combination with Akt1 inhibitor 
(5 µM, Akt124005; Calbiochem), c-Src inhibitor (50 nM, Src I1; Tocris Bioscience) and PI3K inhibitor (5 nM wortmannin; Tocris Bioscience), respectively. 
**P<0.01 and ***P<0.001.
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expression of three key molecules, c-Src, PLCγ and Akt1 
which mediate signalling downstream of the respective recep-
tors of VEGF and FGF. To our surprise, an elevated protein 
level was seen for Akt1 and c-Src in the HECVPTPRKkd cells, 
which was not observed for the PLCγ. An enhanced expres-
sion of Akt1 was seen in the PTPRK knockdown cells when 
they were exposed to the VEGF, while FGF treated cells 
exhibited similar levels of Akt1 protein compared with the 
untreated controls. A similar pattern and expression levels of 
c-Src were seen in the cells treated with VEGF compared with 
the untreated controls, while the FGF-treated HECVPTPRKkd 
cells had a reduced expression of c-Src which was down to 
a similar level of the HECVpEF cells. VEGF increased the 
protein level of PLCγ in both HECVPTPRKkd and HECVpEF 
cells. In contrast to the VEGF-elevated expression of PLCγ, 
an increased protein expression of PLCγ was only seen in the 
PTPRK knockdown cells when they were treated with FGF 
(Fig. 4C). Since an increased response to FGF was seen in 
the migration of PTPRK knockdown cells, we treated cells 
with FGF with additions of small inhibitors targeting c-Src, 
PLCγ, Akt and also PI3K to verify their involvement in the 
FGF-promoted cell motility. Four inhibitors suppressed the 
cell migration which were promoted by FGF, however, only 
the PLCγ inhibitor repressed the migration of HECVPTPRKkd 
cells to a level similar to the control cells (Fig. 4D and E).
Involvement of PTPRK in pro-angiogenic factor and cancer 
cell induced tubule formation of vascular endothelial cells. 
An in vitro tubule formation assay was used to assess the 
influence of PTPRK knockdown on the capability of vascular 
endothelial cells to form new vasculature. Knockdown of 
PTPRK resulted in a decrease of proliferation and cell-matrix 
adhesion, a similar inhibitory effect was also seen in the 
tubule formation (Fig. 5A), though the motility of endothelial 
cells was enhanced after the PTPRK knockdown. We then 
investigated the proangiogenic factor, in particular the VEGF 
and FGF-induced angiogenesis. The reduced tubule forma-
tion in the PTPRK knockdown cells was diminished by an 
exposure to VEGF (10 ng/ml) and the PTPRK knockdown 
cells appeared to be more responsive to VEGF compared with 
the HECVpEF cells but not to a significant level. However, an 
increased tubule formation was seen in both HECVPTPRKkd 
and HECVpEF cells which were treated with FGF (10 ng/ml) 
(1588.92±134.61 vs. 2002.02±96.39 µm; P<0.05). However, the 
PTPRK knockdown-inhibited tubule formation still existed 
when the cells were treated with FGF (Fig. 5B).
To mimic the tumour associated angiogenesis, we treated 
the endothelial cells with medium collected from breast cancer 
cells (MDA-MB-231). We aimed to clarify the involvement of 
PTPRK in cancer cell-induced angiogenesis. Cells incubated 
with 50% medium collected from breast cancer showed 
similar result with FGF treated cells, it promoted both tubule 
formation of HECVPTPRKkd and HECVpEF cells but the PTPRK 
knockdown-inhibited tubule formation was still present 
(1392.87±157.59 vs. 2029.87±204.46 µm; P<0.01) (Fig. 5C).
Discussion
Our previous studies have shown that the expression of PTPRK 
is reduced in the breast cancer which is associated with poor 
prognosis of the disease (26). Knockdown of PTPRK in breast 
cancer cells promoted their proliferation, adhesion, inva-
sion and migration. In contrast to the reduced expression of 
PTPRK observed in the breast cancer, an increased PTPRK 
expression was seen in prostate cancer (25). An inhibitory 
effect on cellular functions was also seen in prostate cancer 
cells following PTPRK knockdown. It suggests that PTPRK 
plays different roles in different cancers which can be cancer 
specific. It has been indicated that some PTPs participate in the 
regulation of angiogenesis. For example, SHP-1 (PTPN6) has 
been identified as an anti-angiogenic regulator via VEGFR2 
signalling pathway (21,33). VE-PTP (PTPRB) plays an impor-
tant role in angiogenesis by targeting the VEGFR2 (34,35) and 
Tie2 pathways (36-39). However, to date, little is known about 
the role of PTPRK in tumour-associated angiogenesis.
In the present study, we first confirmed expression of 
PTPRK in a vascular endothelial cell lines (HECV). PTPRK 
Figure 5. The effects of PTPRK knockdown on cell proliferation and tubule 
formation of HECV cells. (A) Knockdown of PTPRK decreased the growth 
rate of HECV cells. (B) Sum of tubule perimeters with different treat-
ments. (C) PTPRK knockdown impaired the tubule formation induced by 
conditioned medium collected from cancer cells (MDA-MB-231). Tubule 
formation images were captured with phase-contrast microscopy. *P<0.05.
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was found to be extensively expressed by a variety of different 
cell lines, including vascular endothelial cells (HECV), 
colorectal cancer (HT115), pancreatic cancer (PANC-1) and 
fibroblasts (MRC-5). We then employed the anti-PTPRK 
ribozyme plasmid constructs to establish a cell model for the 
present study. Knockdown of PTPRK expression in the HECV 
cells resulted in a decreased proliferation and cell-matrix 
adhesion. This is similar to the inhibitory effect observed in 
the prostate cancer cells with knockdown of PTPRK (25). 
In contrast, PTPRK knockdown promoted migration of the 
endothelial cells which was similar to the effect seen in breast 
cancer cells (26). Such contrasting effects on different cellular 
functions of vascular endothelial cells suggest that PTPRK 
elicits more complex functions by interacting with different 
molecules.
Focal adhesion kinase (FAK)-paxillin signalling pathway 
regulates many cellular functions such as cell survival and 
migration; it has also been indicated that PTPs are involved 
in this mechanism. For example, PTP-PEST interacts with 
paxillin and Grb2 which are key players in the focal adhe-
sion complex (40). DEP-1 (PTPRJ) inhibits cell proliferation, 
formation of vinculin and paxillin-containing adhesion 
plaques and also the activation of FAK (41). DEP-1 can interact 
with c-Src and promotes cell adhesion through an activation 
of FAK and paxillin (42). In the present study, knockdown of 
PTPRK in human endothelia cells reduced cell-matrix adhe-
sion. To examine the involvement of FAK and paxillin in the 
inhibitory effect on cell adhesion of HECV cells, we investi-
gated the protein expression using western blot analysis. The 
results showed that protein levels of both FAK and paxillin 
were decreased in the PTPRK knockdown cells. The reduced 
FAK and paxillin protein levels are in line with the inhibitory 
effect on cell-matrix adhesion. It suggests that PTPRK may 
play a role by either directly mediating the adhesion and/or 
stabilising focal adhesion complex which includes FAK and 
paxillin. However, the exact machinery operated by PTPRK 
in regulation of cell adhesion requires further investigation.
Moreover, knockdown of PTPRK promoted cell motility 
in endothelial cells and cell spreading assay showed us that the 
average cell size of PTPRK knockdown cells were smaller than 
control cell after 30-min incubation. This is consistent with 
the inhibitory effect of PTPRK knockdown on cell adhesion 
and also the reduced FAK and paxillin proteins. The cellular 
spreading of HECV cells following the initial adhesion was 
enhanced by the PTPRK knockdown due to its effect on cell 
migration. Furthermore, fibronectin induced endothelial cell 
migration was regulated by Src-dependent phosphorylation 
of FGFR1 (43). Fibroblast induced cell-contact-dependent 
colorectal cancer cell migration and invasion via regulation 
of the FGF2-FGFRs-Src-αvβ5 pathway (44). In migratory 
glioma-tropic neural stem cells, promotion of VEGFR2 
expression resulted in activation of VEGFR pathway down-
stream molecules such as PLCγ, FAK and Akt (45). Our 
results showed that c-Src and Akt were increased at their 
protein levels after the knockdown of PTPRK. PLCγ appeared 
to be more involved in the FGF induced effect. Along with 
c-Src, PLCγ and Akt, we also included PI3K which is a key 
molecule in mediating signalling for FGF in our experiment 
with small inhibitors. We treated the HECV cells with FGF 
and small inhibitors targeting c-Src, PLCγ, Akt and PI3K. The 
addition of small inhibitors showed that all four molecules 
play important roles in cell migration and were involved in 
the PTPRK knockdown promoted cell migration to various 
levels, in which PLCγ tended to be vital for the migration. 
However, a more comprehensive method is required to deter-
mine PTPRK-regulated protein phosphorylation and signal 
transduction, for example, the Kinex™ antibody microarray 
(Kinexus Bioinformatics Corp., Vancouver, Canada).
Studies have shown that certain PTPs contribute to 
the inhibitory effect on cell proliferation, such as PTPN3 
in cholangiocarcinoma, PTPRM and PTPRK in breast 
cancer (26,46,47). However, studies also showed that same 
PTPs may confer a favour to the proliferation and inhibition of 
PTPRM in glioblastoma multiforme cells has been shown to 
result in decreased cell growth and survival (48). Furthermore, 
our previous studies have also shown that knockdown of 
PTPRK in prostate cancer cells reduces cell proliferation due 
to promotion of apoptosis via JNK pathway (25). In the present 
study, we tried to investigate which pathway was involved in 
the regulation of cell growth in human endothelial cells. Little 
effect was seen in the proliferation of HECV with addition 
of small inhibitors targeting Src, Akt and also PI3K which is 
another key player downstream of the respective receptors of 
VEGF and FGF (data not shown). The mechanism underlying 
the inhibitor effect of proliferation is yet to be elucidated.
A further in vitro tubule formation test showed promotion 
of tubule formation triggered by the knockdown of PTPRK, 
which could be the predominant effect of PTRPK knockdown 
on angiogenesis unless it is further validated by ex vivo and 
in vivo evidence. It has been reported that FGF and VEGF 
pathways participate in the regulation of many cell function 
such as cell motility and angiogenesis (49,50). Reduction of 
PTP1B expression increased VEGF-induced migration and 
proliferation of mouse heart microvascular endothelial cells 
and FGF-induced proliferation of rat aortic smooth muscle 
cells (51). SHP-2 was shown to positively regulate endothelial 
cell motility and angiogenesis in vitro and in vivo (52). To 
elucidate the involvement of PTPRK in the pro-angiogenic 
factors-induced angiogenesis and also the tumour-associated 
angiogenesis, we treated the HECV cells with VEGF, FGF 
and also the conditioned medium from breast cancer cell lines. 
The PTPRK knockdown HECV cells were more responsive 
to the FGF in their migration suggesting a key role played by 
PTPRK in suppression of FGF-induced cell migration. In the 
tubule formation, PTPRK knockdown did not suppress the 
VEGF-induced tubule formation though it exhibited inhibi-
tion on the tubule formation of the untreated cells. In contrast, 
PTPRK knockdown cells tended to be less responsive to the 
FGF treatment. Moreover, the PTPRK knockdown cells were 
less responsive in their tubule formation by an exposure to 
the conditioned medium from breast cancer cells. It suggests 
that PTPRK bears inhibitory effect on the tubule formation 
by suppressing pathways triggered by FGF and cancer cells. 
Therefore, PTPRK may play a positive role in coordinating 
cancer cell induced angiogenesis. Further investigation of 
targeting soluble factors, such as VEGF and FGF released 
from cancer cells using neutralizing antibodies will help to 
expand the current understanding of cancer cell-regulated 
angiogenesis which may help to develop a novel anti-angio-
genic strategy.
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In conclusion, PTPRK knockdown exhibited diverse 
effects on different cellular functions of vascular endothelial 
cells; inhibitory effect on cell proliferation, adhesion and 
tubule formation, but a positive effect on cell migration. A 
positive correlation in the expression between PTPRK and 
focal adhesion complex (FAK and paxillin) contributes to 
the cell adhesion. Reduced PTPRK expression enhanced 
FGF-induced migration, but elicited inhibitory effects on the 
tubule formation that was promoted by FGF and cancer cells. 
PTPRK tends to be less involved in the VEGF-induced tubule 
formation. It suggests that PTPRK plays diverse roles in coor-
dinating angiogenesis which can be more specific to certain 
pro-angiogenic factors.
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